Trevi Therapeutics Files DEF 14A on Executive Compensation
Ticker: TRVI · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1563880
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Trevi Therapeutics DEF 14A out: Executive equity awards and compensation details for 2023-2024.
AI Summary
Trevi Therapeutics, Inc. filed its DEF 14A on April 29, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2023, and December 31, 2024. The filing includes information on the change in fair value of outstanding and unvested equity awards granted in prior years for both principal executive officers (PEO) and non-PEO/non-executive officers.
Why It Matters
This filing provides transparency into how Trevi Therapeutics compensates its top executives and the value of equity awards, which can influence investor decisions and perceptions of company management.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not contain new material events or financial performance data.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Filer of the DEF 14A
- April 29, 2025 (date) — Filing date of the DEF 14A
- December 31, 2023 (date) — Fiscal year end for compensation data
- December 31, 2024 (date) — Fiscal year end for compensation data
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information about matters to be voted on, including executive compensation, director nominations, and other corporate governance issues.
What specific periods does this DEF 14A filing cover for compensation data?
This DEF 14A filing by Trevi Therapeutics, Inc. covers compensation data for the fiscal years ending December 31, 2023, and December 31, 2024.
What type of compensation details are highlighted in this filing?
The filing highlights details regarding the change in fair value of outstanding and unvested equity awards granted in prior years, for both principal executive officers (PEO) and non-PEO/non-executive officers.
Who is the filer of this DEF 14A document?
The filer of this DEF 14A document is Trevi Therapeutics, Inc., with Central Index Key (CIK) 0001563880.
What is the standard industrial classification for Trevi Therapeutics, Inc.?
The standard industrial classification for Trevi Therapeutics, Inc. is Pharmaceutical Preparations [2834].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Trevi Therapeutics, Inc. (TRVI).